Brainsway Ltd ADR (BWAY) Stock Price, Quote & News

Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitatio...

Industry: Medical Devices

Sector: Healthcare

Phone: 972 2 582 4030

Website: www.brainsway.com

Address:

16 Hartum St, Har Hotzvim, Jerusalem, Israel

BoardroomDynamics Dec. 25 at 3:42 PM

$BWAY Capital efficiency and sharper decision‑making are becoming essential drivers of sentiment. The business must show that scaling does not introduce uncontrolled risk. Failure to deliver would likely trigger renewed valuation compression. Future re‑rating depends on turning narrative into measurable outcomes.

0 · Reply

BrainsWay Dec. 25 at 10:34 AM

$BWAY Hadar Levy, CEO of BrainsWay, on expanded adolescent depression coverage for Deep TMS “Optum’s policy expansion marks an important step forward in expanding access to a more effective, clinically proven, and non-drug treatment option for young people affected by MDD. Deep TMS has already changed the trajectory of care for adults facing depression, and extending access to younger patients reflects a shared commitment to early intervention, innovation, and meaningful clinical impact.”

0 · Reply

BrainsWay Dec. 24 at 11:31 AM

$BWAY BrainsWay Unveils SWIFT, A New FDA-Cleared Treatment for Depressive Disorders Watch Dr. Richard A. Bermudes, BrainsWay’s Chief Medical Officer, explain how SWIFT, the accelerated Deep TMS protocol, provides rapid, noninvasive relief for patients with depressive disorders. Watch here: https://ktul.com/living-oklahoma/segments/brainsway-announces-swift-a-new-fda-cleared-option-for-treating-depressive-disorders

0 · Reply

PublishingPips Dec. 24 at 11:19 AM

$BWAY The next phase will be defined by how timelines compress uncertainty rather than extend speculation. Failure to demonstrate progress would likely keep valuation capped.

0 · Reply

ZacksResearch Dec. 23 at 6:12 PM

Big move brewing for $BWAY — reimbursement tailwind just got stronger. 🚀 Optum is expanding Deep TMS coverage to adolescents, giving BrainsWay clearer reimbursement visibility and pushing the stock higher on the news. That’s a meaningful unlock for adoption and revenue confidence. Full details on why this matters here 👉 https://www.zacks.com/stock/news/2808153/bway-shares-gain-on-optum-expanding-deep-tms-coverage-for-teens?cid=sm-stocktwits-2-2808153-teaser-26082&ADID=SYND_STOCKTWITS_TWEET_2_2808153_TEASER_26082

0 · Reply

ZacksResearch Dec. 23 at 5:12 PM

$BWAY just gained 10.1% — what’s driving the surge? 🚀 BrainsWay’s Deep TMS therapy just got a major boost from Optum Behavioral Health, expanding insurance coverage for adolescent depression. This signals stronger payer confidence and widens their commercial opportunity. Full scoop on BWAY’s potential here 👉 https://www.zacks.com/stock/news/2808153/bway-shares-gain-on-optum-expanding-deep-tms-coverage-for-teens?cid=sm-stocktwits-2-2808153-body-26060&ADID=SYND_STOCKTWITS_TWEET_2_2808153_BODY_26060

0 · Reply

BrainsWay Dec. 23 at 9:46 AM

$BWAY BrainsWay Reports Expansion of Adolescent Depression Coverage Applicable to Deep TMS We at BrainsWay are extremely proud to announce that we have expanded our medical policy applicable to Deep TMS™ therapy, now to include coverage for adolescents aged 15 and older with a confirmed diagnosis of major depressive disorder (MDD). Read more about this incredible news here: https://www.brainsway.com/news_events/brainsway-reports-expansion-of-adolescent-depression-coverage-applicable-to-deep-tms/

0 · Reply

dup007 Dec. 22 at 6:49 PM

$BWAY 18.90 +1.79 (+10.46%) As of 1:40:46 PM EST. Market Open. Breaking 52w/h

0 · Reply

JohnTrack Dec. 22 at 4:15 PM

$BWAY keeping it casual, on watch!

0 · Reply

dup007 Dec. 22 at 4:08 PM

$BWAY 18.22 +1.11 +(6.49%) As of 10:59:33 AM EST. Market Open. 52w/h

0 · Reply

BrainsWay Reports Expansion of Adolescent Depression Coverage Applicable to Deep TMS™

Dec 1, 2025, 3:33 PM EST - 23 days ago

BrainsWay Ltd. (BWAY) Analyst/Investor Day Transcript

Nov 25, 2025, 7:30 AM EST - 4 weeks ago

BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company's Growth Strategy and Deep TMS™ Treatment December 1, 2025

Nov 17, 2025, 7:30 AM EST - 5 weeks ago

BrainsWay Launches First Clinical Trial of Deep TMS 360™ System for Alcohol Use Disorder

Nov 13, 2025, 6:00 AM EST - 6 weeks ago

BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21

Nov 11, 2025, 10:41 AM EST - 6 weeks ago

BrainsWay Ltd. (BWAY) Q3 2025 Earnings Call Transcript

Nov 11, 2025, 7:30 AM EST - 6 weeks ago

BrainsWay Reports Third Quarter 2025 Financial Results and Operational Highlights

Nov 4, 2025, 8:00 AM EST - 7 weeks ago

BrainsWay Reports National Institutes of Health Grant to Leading U.S. Research Team Investigating Accelerated Deep TMS for Treatment of Alcohol Use Disorder

Oct 28, 2025, 8:00 AM EDT - 2 months ago

BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025

Oct 27, 2025, 7:30 AM EDT - 2 months ago

BrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health Providers

Aug 21, 2025, 7:30 AM EDT - 4 months ago

BrainsWay Targets Expansion of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd.

Aug 20, 2025, 7:30 AM EDT - 4 months ago

BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health

Aug 13, 2025, 3:21 PM EDT - 4 months ago

BrainsWay Ltd. (BWAY) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 7:30 AM EDT - 4 months ago

BrainsWay Reports Second Quarter 2025 Financial Results and Operational Highlights

Jun 11, 2025, 7:30 AM EDT - 7 months ago

BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)

Jun 10, 2025, 8:00 AM EDT - 7 months ago

BrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society Annual Meeting in San Diego

Jun 4, 2025, 7:30 AM EDT - 7 months ago

BrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO, LLC

May 13, 2025, 10:16 AM EDT - 8 months ago

BrainsWay Ltd. (BWAY) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:30 AM EDT - 8 months ago

BrainsWay Reports First Quarter 2025 Financial Results and Operational Highlights

Mar 11, 2025, 10:17 AM EDT - 10 months ago

BrainsWay Ltd. (BWAY) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 7:30 AM EDT - 10 months ago

BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Dec 12, 2024, 8:00 AM EST - 1 year ago

BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder

Nov 20, 2024, 8:00 AM EST - 1 year ago

BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy

Nov 12, 2024, 12:59 PM EST - 1 year ago

BrainsWay Ltd. (BWAY) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:30 AM EST - 1 year ago

BrainsWay Reports Third Quarter 2024 Financial Results and Operational Highlights

Oct 29, 2024, 8:00 AM EDT - 1 year ago

BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024

Oct 9, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Further Penetrates East Asia with Placement of 15 Additional Deep TMS™ Systems in Taiwan and South Korea

Sep 30, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Announces US$20 Million Private Placement with Valor Equity Partners

Sep 16, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Announces Significant Expansion on U.S. East Coast

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Israel Ministry of Defense Clears BrainsWay Deep TMS™ for PTSD Reimbursement at Israeli Hospitals

Aug 29, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Appoints Richard A. Bermudes, M.D.

Aug 13, 2024, 4:40 AM EDT - 1 year ago

BrainsWay: Operating Leverage Driving Upside

Aug 6, 2024, 12:03 PM EDT - 1 year ago

BrainsWay Ltd. (BWAY) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Reports Second Quarter 2024 Financial Results and Operational Highlights

Jul 23, 2024, 8:00 AM EDT - 1 year ago

BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 17, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Expands Global Imprint with Exclusive Multi-Year Distribution Agreement in Canada

Jun 10, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep TMS™ for Depression

Jun 3, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Receives Expanded FDA Labeling to Treat Late Life Depression

May 9, 2024, 9:00 AM EDT - 1 year ago

BrainsWay: Cash Flows Are Underappreciated

May 8, 2024, 1:16 PM EDT - 1 year ago

BrainsWay Ltd. (BWAY) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Reports First Quarter 2024 Financial Results and Operational Highlights

Apr 24, 2024, 8:00 AM EDT - 1 year ago

BrainsWay to Report First Quarter 2024 Financial Results on May 8, 2024

Apr 4, 2024, 8:00 AM EDT - 1 year ago

BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS™ to Treat Parkinson's Disease

Mar 18, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Broadens Partnership with Katie's Way Plus Through Order of an Additional 18 Deep TMS™ Systems

Mar 6, 2024, 10:04 AM EST - 1 year ago

BrainsWay Ltd. (BWAY) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 7:30 AM EST - 1 year ago

BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights

Feb 21, 2024, 8:00 AM EST - 2 years ago

BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

Jan 10, 2024, 7:30 AM EST - 2 years ago

BrainsWay Initiates Clinical Evaluation of Rotational Field “Deep TMS 360°™” Technology

Dec 19, 2023, 7:30 AM EST - 2 years ago

BrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. Network

Dec 7, 2023, 8:00 AM EST - 2 years ago

BrainsWay Announces Continued Expansion of Deep TMS™ in South Korea

BoardroomDynamics Dec. 25 at 3:42 PM

0 · Reply

BrainsWay Dec. 25 at 10:34 AM

0 · Reply

BrainsWay Dec. 24 at 11:31 AM

0 · Reply

PublishingPips Dec. 24 at 11:19 AM

$BWAY The next phase will be defined by how timelines compress uncertainty rather than extend speculation. Failure to demonstrate progress would likely keep valuation capped.

0 · Reply

ZacksResearch Dec. 23 at 6:12 PM

0 · Reply

ZacksResearch Dec. 23 at 5:12 PM

0 · Reply

BrainsWay Dec. 23 at 9:46 AM

0 · Reply

dup007 Dec. 22 at 6:49 PM

$BWAY 18.90 +1.79 (+10.46%) As of 1:40:46 PM EST. Market Open. Breaking 52w/h

0 · Reply

JohnTrack Dec. 22 at 4:15 PM

$BWAY keeping it casual, on watch!

0 · Reply

dup007 Dec. 22 at 4:08 PM

$BWAY 18.22 +1.11 +(6.49%) As of 10:59:33 AM EST. Market Open. 52w/h

0 · Reply

JohnTrack Dec. 22 at 2:31 PM

$BWAY Expansion of Adolescent Depression Coverage Applicable to Deep TMS https://www.rapidticker.com/news/bway-brainsway-reports-expansion-of-adolescent-71ceb2

0 · Reply

JohnTrack Dec. 22 at 12:31 PM

$BWAY new bulletin for this ticker https://www.rapidticker.com/news/bway-sec-filing-34f586

0 · Reply

NVDAMillionaire Dec. 19 at 10:37 AM

$BWAY Excellent article that nails exactly where BWAY stands right now. So if you want to update your BWAY knowledge or get acquainted with BWAY, this is a must read. https://beyondspx.com/quote/BWAY/analysis/brainsway-s-deep-dive-into-growth-expanding-reach-and-innovation-in-neurostimulation-nasdaq-bway

0 · Reply

prismmarketview Dec. 16 at 8:47 PM

Mental health care is shifting toward higher demand, more digital delivery, and integrated, value‑based models, with tele‑mental health, outpatient counseling, and digital tools growing fastest as services diversify. Talkspace, Inc.( $TALK) BrainsWay Ltd., ( $BWAY) Therapeutics ( $SAGE) VistaGen Therapeutics ( $VTGN) https://prismmarketview.com/mental-health-care-evolves-as-demand-grows-and-services-diversify/

0 · Reply

SuperGreenToday Dec. 15 at 2:05 PM

$BWAY Share Price: $16.85 Contract Selected: Jul 17, 2026 $20 Calls Buy Zone: $1.07 – $1.32 Target Zone: $1.79 – $2.19 Potential Upside: 58% ROI Time to Expiration: 213 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

BrainsWay Dec. 14 at 10:13 AM

$BWAY BrainsWay is proud to announce that Valor Equity Partners, a leading $20B equity firm behind market leaders such as Tesla and PayPal, is now BrainsWay’s largest investor and an active partner in our scale strategy. Valor’s portfolio includes globally recognized market leaders such as: 🔹 Tesla 🔹 SpaceX 🔹 Anduril 🔹 Reddit 🔹 Neuralink 🔹 PayPal 🔹 Uber

0 · Reply

BrainsWay Dec. 11 at 11:27 AM

$BWAY H.C. Wainwright raises Brainsway stock price target to $24 on positive outlook, a 34% increase from the current stock price of $BWAY ($17.85). https://www.investing.com/news/analyst-ratings/hc-wainwright-raises-brainsway-stock-price-target-to-24-on-positive-outlook-93CH-4395865

0 · Reply

Estimize Dec. 11 at 11:00 AM

Wall St is expecting 0.05 EPS for $BWAY Q4 [Reporting 03/11 BMO] http://www.estimize.com/intro/bway?chart=historical&metric_name=eps&utm_co

0 · Reply

JarvisFlow Dec. 8 at 2:38 PM

HC Wainwright & Co. has updated their rating for BrainsWay ( $BWAY ) to Buy with a price target of 24.

0 · Reply

BrainsWay Dec. 8 at 2:03 PM

$BWAY BrainsWay continues to cement its position as a global leader in Transcranial Magnetic Stimulation (TMS), and the momentum is only accelerating. Market leadership highlights include: • Installed base of 1,600+ Deep TMS systems worldwide • More than 7 million individual treatments delivered • Four FDA-cleared indications, including: - 2013 – Major Depressive Disorder (MDD) - 2018 – Obsessive-Compulsive Disorder (OCD) - 2020 – Smoking Addiction - 2021 – Anxious Depression - 2025 – Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21 With established reimbursement pathways, adoption continues to strengthen as Deep TMS becomes increasingly accessible across clinical settings. BrainsWay’s track record of innovation, clinical validation, and market expansion positions the company at the forefront of transformative mental health solutions.

0 · Reply

BrainsWay Dec. 4 at 9:46 AM

$BWAY On December 1, BWAY held a Virtual Analyst and Investor Day to present updates on its growth strategy and the clinical impact of Deep TMS™ for the treatment of mental health and addiction conditions. Key highlights include: - Clinical Insights - Strategic Partnerships - Treatment Overview - Accelerated Protocols - Interactive Q&A Rewatch the event here: https://lifescievents.com/event/hbg2t9aj/

0 · Reply

BrainsWay Dec. 2 at 9:17 AM

$BWAY BrainsWay’s global expansion strategy is supported by large, underserved patient populations and established partnerships across key international markets. Deep TMS™ is positioned to play a transformative role in mental health care far beyond the U.S. International Growth Opportunities Include: • Europe: 37M depression patients • India: 57M depression patients • China: 71M depression patients • Japan: 6M depression patients • Australia: 1.3M depression patients These regions represent some of the largest global markets for depression treatment, offering substantial long-term growth potential. BrainsWay’s expanding network of partners, combined with its proven clinical outcomes and established reimbursement infrastructure, provides a strong platform for accelerated international adoption.

0 · Reply

Market Cap	384.10M
Revenue (ttm)	41.02M
Net Income (ttm)	2.92M
EPS (ttm)	N/A
PE Ratio	62.77
Forward PE	52.31
Profit Margin	7.12%
Debt to Equity Ratio	0.00

Volume	40,800
Avg Vol	72,958
Day's Range	N/A - N/A
Shares Out	19.57M
Stochastic %K	87%
Beta	1.22
Analysts	Strong Sell
Price Target	$22.00